High interest rates, cooling venture capital and an oversupplied market — will the United Kingdom follow the path of the U.S. life sciences real estate market? “Life sciences companies were forced to do more with less in 2023,” says Olivia Drew, portfolio manager, U.K. Life Sciences, with UBS Asset Management, Real Estate & Private Markets, in a report published in the June issue of Institutional Real Estate Europe. Drew compares how the U.K. life sciences market is developing in similar ways, and in different ways, than the U.S. life sciences market. “The global market correction has come at a critical moment for the UK life sciences real estate market and allowed the supply pipeline to adjust and rationalize,” says Drew. “The United Kingdom, therefore, does not face the same issues of oversupply that the United States does.” To access a pdf of the Sponsored Section,
